{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:41:08Z","timestamp":1791243668610,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has significantly improved the treatment outcome of lymphoma patients. Via an elusive mechanism, a subpopulation of patients becomes unresponsive and\/or relapses. To recapitulate various aspects of acquired resistance, rituximab-resistant (RR) clones were established from lymphoma lines and compared with parental cells. Surface CD20 expression was diminished in the clones. The clones neither responded to rituximab-mediated growth reduction or complement-dependent cytotoxicity nor underwent apoptosis in response to cross-linked rituximab. Rituximab failed to chemosensitize the RR clones, which exhibited constitutive hyperactivation of the nuclear factor-\u03baB and extracellular signal-regulated kinase 1\/2 pathways, leading to overexpression of B-cell lymphoma protein 2 (Bcl-2), Bcl-2\u2013related gene (long alternatively spliced variant of Bcl-x gene), and myeloid cell differentiation 1 and higher drug resistance. Unlike parental cells, rituximab neither inhibited the activity of these pathways nor diminished the expression of resistant factors. Pharmacologic inhibitors of the survival pathways or Bcl-2 family members reduced the activity of these pathways, diminished antiapoptotic protein expression, and chemosensitized the RR clones. These novel in vitro results denote that continuous long-term rituximab exposure culminates in RR clones that do not respond to rituximab-mediated effects, have altered cellular signaling dynamics, and exhibit different genetic and phenotypic properties compared with parental cells. The data also reveal that although RR clones exhibit higher resistance to rituximab and cytotoxic drugs, these clones can be chemosensitized following treatment with pharmacologic inhibitors (e.g., dehydroxymethylepoxyquinomicin, bortezomib, PD098059) that target survival\/antiapoptotic pathways. The findings also identify intracellular targets for potential molecular therapeutic intervention to increase treatment efficacy. The significance and potential clinical relevance of the findings are discussed. [Cancer Res 2007;67(3):1270\u201381]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-2184","type":"journal-article","created":{"date-parts":[[2007,2,5]],"date-time":"2007-02-05T13:52:50Z","timestamp":1170683570000},"page":"1270-1281","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy"],"prefix":"10.1158","volume":"67","author":[{"given":"Ali R.","family":"Jazirehi","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario I.","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonavida","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,2,5]]},"reference":[{"key":"2022061623225108800_B1","doi-asserted-by":"crossref","unstructured":"Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood\u20081994; 83: 435\u20135.","DOI":"10.1182\/blood.V83.2.435.bloodjournal832435"},{"key":"2022061623225108800_B2","doi-asserted-by":"crossref","unstructured":"Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL. Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs\u20082002; 2: S43\u201350.","DOI":"10.1097\/00001813-200211002-00007"},{"key":"2022061623225108800_B3","doi-asserted-by":"crossref","unstructured":"Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today\u20081994; 15: 450\u20134.","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"2022061623225108800_B4","doi-asserted-by":"crossref","unstructured":"Andeson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood\u20081984; 63: 1424\u201333.","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"2022061623225108800_B5","doi-asserted-by":"crossref","unstructured":"Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood\u20081987; 69: 584\u201391.","DOI":"10.1182\/blood.V69.2.584.bloodjournal692584"},{"key":"2022061623225108800_B6","doi-asserted-by":"crossref","unstructured":"Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J\u20081988; 7: 711\u20137.","DOI":"10.1002\/j.1460-2075.1988.tb02867.x"},{"key":"2022061623225108800_B7","doi-asserted-by":"crossref","unstructured":"Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol\u20082002; 76: 385\u201393.","DOI":"10.1007\/BF02982803"},{"key":"2022061623225108800_B8","doi-asserted-by":"crossref","unstructured":"Dillman RO. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol\u20082003; 30: 434\u201347.","DOI":"10.1016\/S0093-7754(03)00235-5"},{"key":"2022061623225108800_B9","doi-asserted-by":"crossref","unstructured":"Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol\u20082003; 30: 483\u201392.","DOI":"10.1016\/S0093-7754(03)00239-2"},{"key":"2022061623225108800_B10","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Dreyling M, Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol\u20082003; 30: 16\u201320.","DOI":"10.1053\/sonc.2003.50024"},{"key":"2022061623225108800_B11","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Gertz MA, Fonseca R. Waldensrtrom macroglobulinemia. Lancet Oncol\u20082003; 4: 679\u201385.","DOI":"10.1016\/S1470-2045(03)01246-4"},{"key":"2022061623225108800_B12","unstructured":"Risken NP, Keuning JJ, Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura. Neth J Med\u20081993; 61: 262\u20135."},{"key":"2022061623225108800_B13","doi-asserted-by":"crossref","unstructured":"Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003;26:351\u20134.","DOI":"10.1159\/000072095"},{"key":"2022061623225108800_B14","doi-asserted-by":"crossref","unstructured":"Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest\u20082003; 124: 1242\u20139.","DOI":"10.1378\/chest.124.4.1242"},{"key":"2022061623225108800_B15","doi-asserted-by":"crossref","unstructured":"Weichert ZG, Martinka M, Rivers JK. Intravascular lymphoma presenting as telangectasias: response to rituximab and combination chemotherapy. J Cutan Med Surg\u20082003; 7: 460\u20133.","DOI":"10.1177\/120347540300700606"},{"key":"2022061623225108800_B16","doi-asserted-by":"crossref","unstructured":"Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol\u20082005; 23: 6421\u20138.","DOI":"10.1200\/JCO.2005.06.004"},{"key":"2022061623225108800_B17","doi-asserted-by":"crossref","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene\u20082003; 22: 7359\u201368.","DOI":"10.1038\/sj.onc.1206939"},{"key":"2022061623225108800_B18","doi-asserted-by":"crossref","unstructured":"Jazirehi AR, Bonavida B. Molecular and cellular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: mplications in chemo-sensitization and therapeutic. Oncogene\u20082005; 24: 2121\u201343.","DOI":"10.1038\/sj.onc.1208349"},{"key":"2022061623225108800_B19","doi-asserted-by":"crossref","unstructured":"Jazirehi AR, Vega M, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemo-sensitization of non-Hodgkin's lymphoma B-cells by Rituximab. Cancer Res\u20082004; 64: 7117\u201326.","DOI":"10.1158\/0008-5472.CAN-03-3500"},{"key":"2022061623225108800_B20","doi-asserted-by":"crossref","unstructured":"Jazirehi AR, Huerta S, Cheng G, Bonavida B. Rituximab (chimeric anti -CD20 mAb) inhibits the constitutive NF-\u03baB signaling pathway in non-Hodgkin's lymphoma (NHL) B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res\u20082005; 65: 264\u201376.","DOI":"10.1158\/0008-5472.264.65.1"},{"key":"2022061623225108800_B21","doi-asserted-by":"crossref","unstructured":"Ghosh S, Karin M. Missing pieces in the NF-\u03baB puzzle. Cell\u20082002; 109: S81\u201396.","DOI":"10.1016\/S0092-8674(02)00703-1"},{"key":"2022061623225108800_B22","unstructured":"Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular regulated kinase\/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res\u20082001; 7: 775\u201383."},{"key":"2022061623225108800_B23","doi-asserted-by":"crossref","unstructured":"Wang CU, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemo-resistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB. Nat Med\u20081999; 5: 412\u20137.","DOI":"10.1038\/7410"},{"key":"2022061623225108800_B24","unstructured":"Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel\/NF-kB, STAT and AP-1 transcription factor families. Histol Histopathol\u20082001; 16: 595\u201301."},{"key":"2022061623225108800_B25","doi-asserted-by":"crossref","unstructured":"Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica\u20082006; 91: 715\u20136.","DOI":"10.1200\/jco.2006.24.18_suppl.7514"},{"key":"2022061623225108800_B26","doi-asserted-by":"crossref","unstructured":"Jazirehi AR, Bonavida B. Cellular and molecular characterization of rituximab-resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) clones: development of cross-resistance to cytotoxic stimuli [abstract presented during the 2004 ASH meeting]. Blood\u20082004; 104: 3410.","DOI":"10.1182\/blood.V104.11.3410.3410"},{"key":"2022061623225108800_B27","doi-asserted-by":"crossref","unstructured":"Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Loss of expression of the pro-apoptotic Bcl-2 family proteins Bak and Bax in rituximab- and chemotherapy-resistant non-Hodgkin's lymphoma cells [abstract presented during the 2005 ASH meeting]. Blood\u20082005; 106: 4819.","DOI":"10.1182\/blood.V106.11.4819.4819"},{"key":"2022061623225108800_B28","unstructured":"Jazirehi AR, Gan X-H, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther\u20082003; 2: 1183\u201393."},{"key":"2022061623225108800_B29","doi-asserted-by":"crossref","unstructured":"Nicoletti IG, Migliorati MC, Pagliacci F, Grignani C, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods\u20081991; 139: 271\u20139.","DOI":"10.1016\/0022-1759(91)90198-O"},{"key":"2022061623225108800_B30","unstructured":"Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity using human and other tumor cell lines. Cancer Res\u20081998; 48: 4827\u201333."},{"key":"2022061623225108800_B31","doi-asserted-by":"crossref","unstructured":"Lee W, Mitchell P, Tijan R. Purified transcription factor AP-1 interacts with TPA inducible enhancer elements. Cell\u20081987; 49: 741\u201352.","DOI":"10.1016\/0092-8674(87)90612-X"},{"key":"2022061623225108800_B32","doi-asserted-by":"crossref","unstructured":"Harada H, Takahashi EI, Itoh S, Harada K, Hori TA, Taniguchi T. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a network in the interferon system. Mol Cell Biol\u20081994; 14: 1500\u20139.","DOI":"10.1128\/mcb.14.2.1500-1509.1994"},{"key":"2022061623225108800_B33","doi-asserted-by":"crossref","unstructured":"Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem\u20081995; 270: 27489\u201394.","DOI":"10.1074\/jbc.270.46.27489"},{"key":"2022061623225108800_B34","doi-asserted-by":"crossref","unstructured":"Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol\u20081998; 9: 995\u20131001.","DOI":"10.1023\/A:1008416911099"},{"key":"2022061623225108800_B35","doi-asserted-by":"crossref","unstructured":"Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with mAbs. Blood\u20081998; 91: 1644\u201352.","DOI":"10.1182\/blood.V91.5.1644"},{"key":"2022061623225108800_B36","doi-asserted-by":"crossref","unstructured":"Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-\u03b1-induced nuclear translocation and activation of NF-\u03baB by dehydroxymethylepoxyquino- micin. J Biol Chem\u20082002; 277: 24626\u201330.","DOI":"10.1074\/jbc.M112063200"},{"key":"2022061623225108800_B37","doi-asserted-by":"crossref","unstructured":"Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma\u20082004; 4: 230\u20137.","DOI":"10.3816\/CLM.2004.n.003"},{"key":"2022061623225108800_B38","doi-asserted-by":"crossref","unstructured":"Tzung S-P, Kim CM, Basanez G, et al. Antimycin A mimics a cell death-inducing Bcl-2 homology domain 3. Nat Cell Biol\u20082001; 3: 183\u201391.","DOI":"10.1038\/35055095"},{"key":"2022061623225108800_B39","doi-asserted-by":"crossref","unstructured":"Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood\u20082004; 104: 1166\u201373.","DOI":"10.1182\/blood-2004-01-0277"},{"key":"2022061623225108800_B40","doi-asserted-by":"crossref","unstructured":"Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol\u20082004; 172: 3280\u20138.","DOI":"10.4049\/jimmunol.172.5.3280"},{"key":"2022061623225108800_B41","doi-asserted-by":"crossref","unstructured":"Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol\u20082003; 70: 330\u20132.","DOI":"10.1034\/j.1600-0609.2003.00007.x"},{"key":"2022061623225108800_B42","doi-asserted-by":"crossref","unstructured":"Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood\u20082003; 101: 2507\u201313.","DOI":"10.1182\/blood-2002-06-1639"},{"key":"2022061623225108800_B43","doi-asserted-by":"crossref","unstructured":"Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemo-therapy resistance: molecular interaction maps and networks. Oncogene\u20082004; 23: 2934\u201349.","DOI":"10.1038\/sj.onc.1207515"},{"key":"2022061623225108800_B44","doi-asserted-by":"crossref","unstructured":"Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene\u20082004; 23: 2838\u201349.","DOI":"10.1038\/sj.onc.1207556"},{"key":"2022061623225108800_B45","doi-asserted-by":"crossref","unstructured":"Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-xL can confer a multi-drug resistance phenotype. Blood\u20081995; 86: 1903\u201310.","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903"},{"key":"2022061623225108800_B46","unstructured":"Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Jr., Fornace A. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res\u20082000; 60: 6101\u201310."},{"key":"2022061623225108800_B47","doi-asserted-by":"crossref","unstructured":"Jazirehi AR, Bonavida B. Sensitization of rituximab-sensitive and rituximab-resistant B-NHL cell lines\/clones to TRAIL-induced apoptosis by Bortezomib and NF\u03baB inhibitors. Blood\u20082005; 106: 1514.","DOI":"10.1182\/blood.V106.11.1514.1514"},{"key":"2022061623225108800_B48","unstructured":"Kikuchi E, Horiguhi Y, Nakashima J, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor \u03baB inhibitor in nude mice. Cancer Res\u20082003; 63: 107\u201310."},{"key":"2022061623225108800_B49","doi-asserted-by":"crossref","unstructured":"O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol\u20082005; 23: 676\u201384.","DOI":"10.1200\/JCO.2005.02.050"},{"key":"2022061623225108800_B50","unstructured":"Jazirehi AR, Bezombes C, Laurant G, Libra M, Bonavida B. Characteristics of rituximab-resistant B-NHL clones: deficiencies in rituximab-mediated changes in lipid raft micro-domains and cell signaling. Proc AACR 2006;47:4657."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/3\/1270\/2577995\/1270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/3\/1270\/2577995\/1270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:14:01Z","timestamp":1655421241000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/3\/1270\/533970\/Development-of-Rituximab-Resistant-Lymphoma-Clones"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2007,2,5]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-2184","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,1]]}}}